Skip to content
value.today
InflaRx N.V. logo

InflaRx N.V.

IFRX
$301 Mmarket cap on Aug 1, 2026+178.7% since Jan 2024
Compare
World rank
#14,740
Revenue
$0 M
For year ending December-2025
Net income
$-51 M
-171533.3% margin
SEC filing
Employees
—

InflaRx N.V. in brief

InflaRx N.V. is a listed company in the Biotechnology industry, based in Germany. Its market value was $301 M on 1 August 2026, which makes it the 14,740th largest listed company in the world and the 208th largest in Germany on this site. In the year to December 2025 it had sales of $0 M and a net loss of $51 M. Niels Riedemann is its chief executive. Its shares trade under the symbol IFRX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

InflaRx N.V. timeline

3 events, 2017
  1. 2017
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. ✎
    Renamed InflaRx N.V.
    Formerly Fireman B.V..
  4. 🔔
    Initial public offering as Fireman B.V.
    Final prospectus filed with the SEC on 8 November 2017; shares registered for exchange trading on 7 November 2017.

Events of InflaRx N.V. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$81 M$163 M$244 M$325 M2020202120222023202420252026

World rank over time

▲ up 4,731 places since 2020
2020-01-01: #18915#18,91520202021-01-01: #16829#16,82920212022-01-07: #20092#20,09220222022-12-25: #19780#19,78020222023-07-30: #17055#17,05520232024-01-05: #21018#21,01820242026-03-08: #10758#10,75820262026-08-01: #14184#14,1842026

Rank in Germany: #374 (Jan 2020) · #348 (Jan 2021) · #331 (Jan 2022) · #313 (Dec 2022) · #272 (Jul 2023) · #327 (Jan 2024) · #4 (Mar 2026) · #210 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
10033.3×
Price / book
35.7×
Free cash flow yield
-13.3%
Net margin (TTM)
-171533.3%
Operating margin
—
Return on equity
-610.4%
Liabilities / assets
24.7%
Revenue growth
-83.3%
R&D / revenue
96700.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-35M—FY18Fiscal year ending Dec 2019: revenue —, net income $-60M—FY19Fiscal year ending Dec 2020: revenue —, net income $-39M—FY20Fiscal year ending Dec 2021: revenue —, net income $-54M—FY21Fiscal year ending Dec 2022: revenue —, net income $-31M—FY22Fiscal year ending Dec 2023: revenue $0M, net income $-46M$0MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-50M$0MFY24Fiscal year ending Dec 2025: revenue $0M, net income $-51M$0MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$0M-83.3%—$-51M-171533.3%
Dec 2024$0M+157.1%—$-50M-27694.4%
Dec 2023$0M—$-49M$-46M-65885.7%
Dec 2022——$-34M$-31M—
Dec 2021——$-56M$-54M—
Dec 2020———$-39M—
Dec 2019———$-60M—
Dec 2018———$-35M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-40M$0M$-40M$-0.77—
Dec 2024$-53M$0M$-53M$-0.84—
Dec 2023$-41M$0M$-41M$-0.84—
Dec 2022$-35M$0M$-36M$-0.70—
Dec 2021$-47M$0M$-47M$-1.30—
Dec 2020$-42M$0M$-42M$-1.44—
Dec 2019$-48M————
Dec 2018$-25M————

SEC filings

Official filings of InflaRx N.V. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
—
Net income
$-51 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$65 M
Total liabilities
$16 M
Total equity
$8 M

As of December-2025

Top 64 institutional investors in InflaRx N.V.#

As of Sep 30, 2026
64 institutions held 100.8 M shares on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in InflaRx N.V.
#InstitutionShares heldChange (shares)ValueFiled
1Montanova Capital, LLC22,933,9100 (0.00%)$41 MNov 16, 2026
2TCG Crossover Management, LLC14,500,0000 (0.00%)$26 MNov 16, 2026
3FMR LLC9,305,472+1,142,131 (+13.99%)$17 MNov 10, 2026
4Commodore Capital LP9,268,220+1,968,220 (+26.96%)$17 MNov 16, 2026
5Spruce Street Capital LP6,086,170+733,972 (+13.71%)$11 MNov 13, 2026
6683 Capital Management, LLC4,690,000-375,000 (-7.40%)$8 MNov 16, 2026
7Farallon Capital Management, L.L.C.3,310,000-15,000 (-0.45%)$6 MNov 16, 2026
8Ameriprise Financial Inc3,093,460+520,661 (+20.24%)$6 MNov 16, 2026
9Great Point Partners LLC3,046,5570 (0.00%)$5 MNov 16, 2026
10ADAR1 Capital Management, LLC3,000,0000 (0.00%)$5 MNov 16, 2026
11Kalehua Capital Management LLC2,921,095-2,874,443 (-49.60%)$5 MNov 13, 2026
12Nantahala Capital Management, LLC2,693,948New$5 MNov 13, 2026
13Stempoint Capital LP2,485,233-743,022 (-23.02%)$4 MNov 16, 2026
14Woodline Partners LP2,105,4860 (0.00%)$4 MNov 16, 2026
15Eversept Partners, LP1,355,382+51,313 (+3.93%)$2 MNov 16, 2026
16Millennium Management LLC1,027,158+460,109 (+81.14%)$2 MNov 16, 2026
17BNP Paribas Financial Markets1,000,311+868,473 (+658.74%)$2 MNov 12, 2026
18Marshall Wace, LLP995,319+284,023 (+39.93%)$2 MNov 13, 2026
19DCF Advisers, LLC975,000+746,500 (+326.70%)$2 MNov 4, 2026
20Jefferies Financial Group Inc.717,074-58,275 (-7.52%)$1 MNov 5, 2026
21Citadel Advisors LLC714,492+575,202 (+412.95%)$1 MNov 16, 2026
22Morgan Stanley559,830-355,784 (-38.86%)$1 MNov 13, 2026
23T3 Companies, LLC440,000+108,986 (+32.92%)$1 MOct 22, 2026
24Point72 Asset Management, L.P.433,893New$1 MNov 16, 2026
25UBS Group AG383,288+304,155 (+384.36%)$1 MNov 10, 2026

All 64 institutional investors: 26 to 64, with who bought and sold →

Mutual funds holding InflaRx N.V.#

7 funds hold shares worth $15 M (about 4.9% of the company). Since their previous reports 5 added shares and 1 sold, buying $15 M net.
Mutual funds holding InflaRx N.V.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC3.29 M$6 M1.9%0.06%newJul 31, 2026
🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC3.20 M$5 M1.8%0.25%newJul 31, 2026
🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC1.68 M$3 M0.95%0.06%newJul 31, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.376,105$1 M0.21%0.06%newJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC43,672$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC23,128$0 M0.01%<0.01%−13%Jun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,363$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Markets and events: InflaRx N.V.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
12.8 M
15.02 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 9,915 shares at $1.55
  • : 172,480 shares at $1.59
  • : 276 shares at $1.89
  • : 869 shares at $2.08
  • : 13,699 shares at $2.06

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

InflaRx N.V. scorecard#

Passes 0 of the 6 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
  • Growth0 of 2
  • Profitability0 of 3
  • Financial health0 of 1
  • Shareholder returnsnot known

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

InflaRx N.V.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in EUR millions; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

InflaRx N.V.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0.00.20.1———————
Cost of revenue7.33.30.5———————
Gross profit−7.2−3.2−0.5————−38−20−7.1
Research and development2635413836264525r14r5.3
Selling, general and administrative0.00.00.10.1r0.1r8.51313r5.1r1.8
Selling and marketing4.56.84.0———————
Total costs and expenses———524834573820—
Operating income——−45−32−48—————
Interest and finance income1.83.23.80.60.10.92.8r2.2r0.1r0.0
Interest expense and finance costs0.00.00.00.00.0r0.0r−0.0r0r4.9r2.0
Provision for credit losses———−4.2−6.86.0————
Income before tax−46−46−43−29−46−34−53−30r−24r−8.9
Income tax0.00.0——000000
Income from continuing operations————————−19−6.9
Net income including minority interests−46−46−43−29−46−34−53−30r−24r−8.9
Earnings per share, basic-0.68-0.78-0.78-0.67-1.10-1.26————
Earnings per share, diluted-0.68-0.78-0.78-0.67-1.10-1.26————
Shares, weighted average (basic)67595544422726———
Shares, weighted average (diluted)————42272625r9.4r0.0
Balance sheet
Cash and cash equivalents1618131626263355r123r29r
Inventory—6.911———————
Other current assets3.35.14.0r14113.7————
Current assets5472109r979686119158r12429
Property, plant and equipment0.30.30.30.30.30.40.6r0.6r0.2—
Right-of-use (leased) assets0.90.81.11.31.40.50.8———
Other intangible assets———0.10.20.40.50.2r0.00.0
Non-current assets1.64.4115.029r1.92.61.1r0.20.1
Total assets5576120r10212588122159r12430
Accounts payable5.411125.08.68.3126.7r4.5r1.5
Current liabilities131417r131910147.8r4.8r1.7
Lease liabilities (non-current)0.60.40.71.01.10.20.30——
Non-current liabilities0.70.40.81.01.10.30.40.1r0.053
Total liabilities141518142010147.8r4.8—
Retained earnings−378−332−286−243−214−168−134−81r−51−27
Shareholders' equity7.27.47.47.33.1—————
Total equity42611038810578107151r119r−26r
Total liabilities and equity557612010212588122159r12430
Cash-flow statement
Share-based compensation4.44.13.46.04.31.1————
Cash from operating activities−35−49−38−34−40r−37−43−22r−12r−5.0
Capital expenditure−0.1−0.0−0.1−0.2−0.0−0.1————
Intangible assets bought————−0.0−0.1r−0.6r−0.8r−0.1r−0.1
Cash from investing activities3.252−1819−262120−99r−0.2r−0.1
Debt repaid−0.4−0.4−0.4−0.4−0.4r−0.4r−0.3r00—
Shares issued231.1562.3659.8————
Cash from financing activities330.4531.9629.2−0.350r109r31
Exchange-rate effect on cash−3.61.4−1.02.54.6−1.20.93.5r−2.3r0.0
Change in cash1.24.2−2.5−12−4.3−6.0−23r−71r94r26
Report20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F/A

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

How InflaRx N.V. compares in Biotechnology

  • Market cap$301 M · higher than 51% of 726
  • Revenue$0 M · higher than 13% of 647
  • Revenue growth-83.3% · higher than 5% of 438
  • Price / book35.7× · lower than 5% of 534
  • FCF yield-13.3% · higher than 52% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
InflaRx N.V.🇩🇪$301 M——-83.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 21, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at InflaRx N.V.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show InflaRx N.V.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about InflaRx N.V.? Suggest a correction